Cases in which ESCC patients had high expression of both Beclin-1 and Bcl-2 showed significantly longer survival than those with low expression of Beclin-1 (high expression of both Beclin-1 and Bcl-2 group vs. low expression of Beclin-1 and high expression of Bcl-2 group; 52.44 ± 4.72 vs. 27.92 ± 2.44; p < 0.01; Figure 2C). This evidence concerns the gene BCL2 and esophageal squamous cell carcinoma.